156 related articles for article (PubMed ID: 11683535)
1. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
Terpos E; Palermos J; Viniou N; Vaiopoulos G; Meletis J; Yataganas X
Calcif Tissue Int; 2001 May; 68(5):285-90. PubMed ID: 11683535
[TBL] [Abstract][Full Text] [Related]
2. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
[TBL] [Abstract][Full Text] [Related]
4. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
5. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.
Abildgaard N; Rungby J; Glerup H; Brixen K; Kassem M; Brincker H; Heickendorff L; Eriksen EF; Nielsen JL
Eur J Haematol; 1998 Aug; 61(2):128-34. PubMed ID: 9714526
[TBL] [Abstract][Full Text] [Related]
6. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma.
Abildgaard N; Glerup H; Rungby J; Bendix-Hansen K; Kassem M; Brixen K; Heickendorff L; Nielsen JL; Eriksen EF
Eur J Haematol; 2000 Feb; 64(2):121-9. PubMed ID: 10997332
[TBL] [Abstract][Full Text] [Related]
7. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
Patel CG; Yee AJ; Scullen TA; Nemani N; Santo L; Richardson PG; Laubach JP; Ghobrial IM; Schlossman RL; Munshi NC; Anderson KC; Raje NS
Clin Cancer Res; 2014 Aug; 20(15):3955-61. PubMed ID: 24958808
[TBL] [Abstract][Full Text] [Related]
9. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates.
Rosen HN; Moses AC; Garber J; Ross DS; Lee SL; Greenspan SL
Calcif Tissue Int; 1998 Nov; 63(5):363-8. PubMed ID: 9799818
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients.
Alexandrakis MG; Passam FH; Malliaraki N; Katachanakis C; Kyriakou DS; Margioris AN
Clin Chim Acta; 2002 Nov; 325(1-2):51-7. PubMed ID: 12367766
[TBL] [Abstract][Full Text] [Related]
11. Markers of bone resorption in patients treated with pamidronate.
Lipton A; Demers L; Curley E; Chinchilli V; Gaydos L; Hortobagyi G; Theriault R; Clemens D; Costa L; Seaman J; Knight R
Eur J Cancer; 1998 Dec; 34(13):2021-6. PubMed ID: 10070304
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
13. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation.
Withold W; Arning M; Schwarz M; Wolf HH; Schneider W
Clin Chim Acta; 1998 Jan; 269(1):21-30. PubMed ID: 9498101
[TBL] [Abstract][Full Text] [Related]
17. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of pamidronate in human multiple myeloma.
Kondo H; Mori A
Leuk Lymphoma; 2002 Apr; 43(4):919-21. PubMed ID: 12153188
[TBL] [Abstract][Full Text] [Related]
19. [Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab].
Tatekoshi A; Sato T; Ibata S; Hashimoto A; Kamihara Y; Horiguchi H; Ono K; Takada K; Iyama S; Takimoto R; Kobune M; Kato J
Rinsho Ketsueki; 2014 Nov; 55(11):2271-6. PubMed ID: 25501406
[TBL] [Abstract][Full Text] [Related]
20. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.
Minisola S; Pacitti MT; Rosso R; Pellegrino C; Ombricolo E; Pisani D; Romagnoli E; Damiani C; Aliberti G; Scarda A; Mazzuoli SF
J Endocrinol Invest; 1997 Oct; 20(9):559-65. PubMed ID: 9413811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]